NYSE:ZBH - New York Stock Exchange, Inc. - US98956P1021 - Common Stock - Currency: USD
Zimmer Biomet Holdings (NYSE:ZBH) offers a reliable dividend with strong profitability and reasonable valuation, making it a solid pick for income investors.
ZIMMER BIOMET HOLDINGS (NYSE:ZBH) is an undervalued medical device stock with strong profitability, reasonable debt, and improving growth prospects, making it a candidate for value investors.
Mentions: TMCI
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: SYK
Thornal will join the orthopedics company as group president for global businesses and the Americas, a newly created position.
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
We recently published a list of 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Salesforce Inc. (NYSE:CRM) stands against other AI stocks on Wall Street’s radar. Days after the Biden-era rule on AI chips export was rescinded, a bipartisan group of eight U.S. lawmakers […]
We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where Zimmer Biomet Holdings, Inc. (NYSE:ZBH) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed better in 2025 compared to the broader market. […]
Mentions: BLK
The new plant will employ more than 110 individuals.
Mentions: BA
Style Box ETF report for MOAT
Zimmer Biomet expects that the majority of tariff impact on profits will be incurred in the second half of the year.
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
Zimmer now expects 2025 adjusted profit per share in the range of $7.90 to $8.10, compared with its prior forecast of $8.15 to $8.35 per share.
Zimmer Biomet Holdings on Monday lowered its 2025 adjusted profit forecast, and said it expects the proposed trade tariffs to weigh on the company's earnings this year. Zimmer, which makes devices used in hip and knee procedures, said it sees an impact of $60 million to $80 million on its operating profit, with a majority in the second half of the year. It sees a less than $5 million impact in the second quarter.
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.